Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Efficacy and Safety of Paxlovid for COVID-19
NCT05532852Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jul 2022
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: 28-day mortality. Status: unknown.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05532852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532852.